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Abstract A library of N1-arylated 5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-
2-ones has been synthesized starting with unsymmetrical diaryliodonium 
salts using aqueous ammonia as a base. This can also be applied to a similar 
1,3,4-benzotriazepin-2-one derivative.  
Key words Benzodiazepines, N-arylation, iodonium salt, privileged scaffold, 
benzotriazepine. 
 
Compounds containing a1,4-benzodiazepine scaffold are often 
termed as ‘privileged structures’ and are of  significant interest 
to organic and medicinal chemists.1-18 Many bioactive 1,4- 
benzodiazepines include N-arylated benzodiazepines; for 
example, the benzodiazepine derivative, A (Figure 1), is a 
bradykinin antagonist19 and the related benzotriazepine B is an 
antagonist at the parathyroid hormone (PTH)-1 receptor.20 
Typically N-arylated benzodiazepines can be prepared by 
transition-metal catalysed couplings, often with copper, with 
various arylating agents. Generally, the reaction scope is limited 
with these routes and often require high temperatures and 
strong bases. 19,21-23 
Being able to generate libraries of diverse analogues, in this case 
by adding N-functionality to a privileged core unit, using mild 
and efficient methodologies, can substantially improve SAR 
studies (structure – activity relationship) and optimise the drug 
development process potentially repurposing privileged 
scaffolds for new biological targets. 24,25 
 
Figure 1 Bioactive N-arylated benzodiazepine and benzotriazepine 
We have an active interest in benzodiazepines 26,27 and recently 
reported a method to functionalise 5-phenyl-1,3-dihydro-2H-
1,4-benzodiazepin-2-ones via a late-stage palladacycle assisted 
ortho C-H activation protocol.28,29  Herein we present our 
approach to generate a series of N1-arylated 1,4-
benzodiazepines using diaryliodonium salts. The latter react 
with nucleophiles in the absence of transition metal catalysts 
and are commonly used in organic synthesis as electrophilic 
reagents. 30-35 
Novak et al. recently reported a protocol for the N-arylation of 
pyrazoles.36 A quick screen of conditions, adapting this protocol 
using diaryliodonium salts with weak bases under mild 
conditions, showed that it was indeed possible to perform 
similar arylations on the 1,4-benzodiazepine system. Upon 
initial screening of a number of solvents, DCE (1,2-
dichloroethane) was found to give the best results (Table 1, 
entry 2). Solvents such as PEG (polypropylene glycol) and acetic 
acid gave poor yields. Similar results were observed on 
pyrazoles by Novak et al. where apolar solvents, immiscible in 
water, produced the best results.  
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Table 1 Optimization of N-arylation of 1,4-benzodiazepines – solvent effects 
 
Entry Solvent Conversion %a  
1 Toluene 95 
2 DCE 99 
3 PEG - 
4 AcOH - 
5 Chloroform 85 
a LCMS conversion. 
 
A number of bases were tested subsequently and both NH3 
(25% w/w) and NaOH (sat. aq.) gave similar and the best results 
(Table 2, entry 1, 2). 
Table 2 Optimization of N-arylation of 1,4-benzodiazepines – base effects 
 
Entry Base Conversion %a 
1 NaOH (sat. aq.) 99 
2 NH3 (25% w/w) 99 
3 K2CO3 80 
4 NaH - 
a LCMS conversion. 
 
Hence, optimal condition appeared to use NH3 (aq.), DCE at room 
temperature for 30 min. Next, a series of functionalized 1,4-
benzodiazepines was N-arylated using (4-
nitrophenyl)phenyliodonium triflate in good to excellent yields 
(Scheme 1). Generally, in transition-metal-free processes 
unsymmetrical diaryliodonium salts give a mixture of products 
where both groups are transferred and the transfer of more 
sterically hindered and electron withdrawing group is 
preferable.34 However, in this case (Scheme 1) only the 
nitrophenyl-group was transferred. We were able to N-arylate 
quite sterically hindered benzodiazepines such as 3e, 3f and 3g. 
Of note, 3e is a key intermediate towards A, the bradykinin B2 
receptor antagonist. We were also pleased to be able to conduct 
N-arylation on a previously ortho-arylated hindered 
benzodiazepine, 3h, in good yield, whose structure was also 
confirmed by X-ray crystallography. Such molecules may be 
useful precursors to e.g., alpha-helical mimetics in medicinal 
chemistry.37,38 
 
Scheme 1 N-arylated 1,4-benzodiazepines 
 
The use of other unsymmetrical diaryliodonium triflates was 
also explored (Table 3), which required longer reaction time 
and led to both aryl groups being transferred to obtain 3i – 3l.  
As expected, the transfer of more sterically hindered or less 
electron rich groups was preferred. Further attempts to use 
unsymmetrical diaryliodonium salts such as phenyl(3-
methylphenyl)iodonium triflate, phenyl(4-
methylphenyl)iodonium triflate and (2-methylphenyl)(2,4,6-
trimethylphenyliodonium triflate gave little or no products. 
Additionally, attempted N-arylation with symmetrical 
diaryliodonium triflates or tetrafluoroborates such as bis(2-
fluorophenyl)iodonium tetrafluoroborate and bis(4-
bromophenyl)iodonium triftlate, gave, at best, traces of 
products.  
 
Table 3 Further N-arylation of 1,4-benzodiazepines 
Salt Product  (major) Product  (minor) 
 
 
  
 
  
Reaction time = 8 h. 
 
We have briefly explored the N-arylation on a 1,3,4-
benzotriazepine, 6, which resulted in di-arylation and yielded 7 
(Scheme 2).  
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Scheme 2 N-arylation on a 1,3,4-benzotriazepine 
 
Interestingly, the iodonium salts were observed to undergo 
reaction with water present in the reaction to give diarylether 
products. The ether product is only observed in substantial 
amounts when the benzodiazepine substrates react poorly with 
the diaryliodonium salts (Table 4). The ether product 10 was 
also obtained merely by stirring the iodonium salt with water in 
DCE with a mild base for 20 min at room temperature with a 
yield of 43%. Olofsson et al. have reported the synthesis of 
related diarylethers by reacting diaryliodonium salts with 
phenols in the presence of mild bases. 39 
Table 4 Diaryl ether formation   
Substrate Expected product Observed product 
 
 
  
 
 
 
In summary we have presented a mild metal-free route to N-
arylated benzodiazepines, three of which were structurally 
characterized in the solid state (3a, 3h, 3i, with CCDC numbers 
1560492-1560494 respectively.40 
Experimental Section 
All reactions were conducted under an inert atmosphere unless 
specified otherwise. All commercially purchased materials and 
solvents were used without further purification unless specified 
otherwise.   
NMR spectra were recorded on a Varian VNMRS 500 (1H: 500 
MHz, 13C: 126 MHz) spectrometer and prepared in deuterated 
solvents such as CDCl3 and DMSO-d6. 1H and 13C chemical shifts 
were recorded in parts per million (ppm). Multiplicity of 1H-
NMR peaks are indicated by s – singlet, d – doublet, dd – 
doublets of doublets, t – triplet, pt – pseudo triplet, q – quartet, 
m – multiplet and coupling constants are given in Hertz (Hz).  
Electrospray ionisation – high resolution mass spectra (ESI-
HRMS) were obtained using a Bruker Daltonics Apex III where 
Apollo ESI was used as the ESI source. Most analyses were 
conducted by Dr A. K. Abdul-Sada at Sussex. The molecular ion 
peaks [M]+ were recorded as mass to charge (m/z) ratio. A 
portion of the high-resolution mass spectrometry (HRMS) 
measurements were also performed by the EPSRC National 
Mass Spectrometry Facility, University of Swansea.  
LC-MS spectra were acquired using a Shimadzu LC-MS 2020, on 
a Gemini 5 µm C18 110 Å column and percentage purities were 
run over 30 minutes in water/acetonitrile with 0.1% formic acid 
(5 min at 5%, 5%-95% over 20 min, 5 min at 95%) with the UV 
detector at 254 nm. Purifications were performed by flash 
chromatography on silica gel columns or C18 columns using a 
Combi flash RF 75 PSI, ISCO unit. 
General Procedure 
To a stirred solution of the appropriate 1,4-benzodiazepine or 
1,3,4-benzotriazepine (0.030 mmol – 1.00 mmol, 1 eq.) and 
diaryliodonium salt (0.033 – 1.10  mmol, 1.1 eq.)  in DCE (5 – 10 
mL) was added 25% w/w NH3 solution (aq. 5 - 10 mL) and the 
reaction mixture was stirred for 30 min. (unless stated 
otherwise). Upon completion, the reaction mixture was diluted 
with dichloromethane (3x15 mL) and the layers were separated. 
Combined organic layers were dried (MgSO4), concentrated 
under reduced pressure and purified by column 
chromatography, hexane/ethyl acetate (80:20 to 30:70). 
1-(4-Nitrophenyl)-5-methyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3a)  
The product was obtained as white solid (0.60 mmol scale, 170 
mg, 96%). 1H-NMR (500 MHz) CDCl3: δ = 8.27 – 8.21 (m, ArH, 
2H), 7.62 (dd, 3JHH = 7.5, 1.5 Hz, ArH, 1H), 7.40 – 7.35 (m, ArH, 
3H), 7.34 – 7.29 (m, ArH, 1H), 6.82 (d, 3JHH = 8.0 Hz, ArH, 1H), 
4.70 (d, 2JHH = 10.5 Hz, COCH2, 1H), 3.83 (d, 2JHH = 10.5 Hz, 
COCH2, 1H), 2.62 (s, CH3, 3H). 13C-NMR (126 MHz) CDCl3: δ = 
170.1 (C=O), 168.1 (C=N), 146.7 (ArC), 146.0 (ArC), 140.8 (ArC), 
131.4 (ArC), 131.3 (ArC), 128.7 (ArC x 2), 127.8 (ArC), 125.9 
(ArC), 125.1 (ArC), 124.5 (ArC x 2), 56.6 (COCH2), 25.5 (CH3). 
HRMS-ESI (m/z) calculated for C16H13N3O3 [+H] +: 296.1030, 
found: 296.1033. LCMS purity (UV) =  100%, tR 8.10 min. 
1-(4-Nitrophenyl)-5-(propan-2-yl)-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3b) 
The product was obtained as a white solid (0.52 mmol scale, 
166 mg, 99%). 1H-NMR (500 MHz) CDCl3: δ = 8.27 – 8.20 (m, 
ArH, 2H), 7.59 (dd, 3JHH = 7.5, 2.0 Hz, ArH, 1H), 7.39 – 7.35 (m, 
ArH, 3H), 7.34 – 7.30 (m, ArH, 1H), 6.83 (dd, 3JHH = 8.0, 1.5 Hz, 
ArH, 1H), 4.72 (d, 2JHH = 10.5 Hz, COCH2, 1H), 3.82 (d, 2JHH = 10.5 
Hz, COCH2, 1H), 3.34 – 3.25 (m, 1H), 1.35 (d, 3JHH = 7.0 Hz, 
CNCHC2CH6, 3H), 1.11 (d, 3JHH = 7.0 Hz, CNCHC2CH6, 3H). 13C-
NMR (126 MHz) CDCl3: δ = 176.9 (C=O), 168.7 (C=N), 146.7 
(ArC), 145.9 (ArC), 141.5 (ArC), 131.6 (ArC), 130.9 (ArC), 128.3 
(ArC x 2), 127.0 (ArC), 126.0 (ArC), 125.0 (ArC), 124.5 (ArC x 2), 
56.5 (COCH2), 35.6 (CNCHC2H6), 22.0 (CNCHC2H6), 19.2 
(CNCHC2H6). HRMS-ESI (m/z) calculated for C18H17N3O3 [+H]+: 
324.1270, found: 324.1281. LCMS purity (UV) = 96 %, tR 18.73 
min. 
1-(4-Nitrophenyl)-3-(propan-2-yl)-5-(propan-2-yl)-1,3-
dihydro-2H-1,4-benzodiazepin-2-one (3c) 
The product was obtained as white solid (0.25 mmol scale, 91 
mg, 99%). 1H-NMR (500 MHz) CDCl3: δ = 8.25 – 8.18 (m, ArH, 
2H), 7.61 (dd, 3JHH = 8.0, 1.5 Hz, ArH, 1H), 7.39 – 7.24 (m, ArH, 
4H), 6.85 (dd, J = 8.0, 1.5 Hz, ArH, 1H), 3.27 (hept, 3JHH = 7.0 Hz, 
CNCHCH3CH3, 1H), 3.12 (d, 3JHH = 9.5 Hz, COCHCHC2H6, 1H), 2.72 
– 2.61 (m, COCHCHC2H6, 1H), 1.33 (d, 3JHH = 7.0 Hz, CNCHC2H6, 
3H), 1.07 (d, 3JHH = 7.0 Hz, CNCHC2CH6, 3H), 1.05 – 1.02 (m, 
COCHCHC2H6, 6H). 13C-NMR (126 MHz) CDCl3: δ = 173.9 (C=O), 
168.3 (C=N), 147.4 (ArC), 145.7 (ArC), 141.1 (ArC), 131.9 (ArC), 
130.6 (ArC), 128.4 (ArC x 2), 126.8 (ArC), 125.7 (ArC), 125.1 
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(ArC), 124.4 (ArC x 2), 69.3 (COCHCHC2H6), 35.5 (CNCHCH3CH3), 
22.2 (COCHCHC2H6), 21.9 (CNCHC2H6), 20.1, (CNCHC2H6) 19.3 
(COCHCHC2H6), 18.7 (COCHCHC2H6).  HRMS-ESI (m/z) 
calculated for C21H23N3O3 [+H] +: 366.1812, found: 366.1816. 
LCMS purity (UV) =  95%, tR 23.47 min. 
1-(4-Nitrophenyl)-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3d) 
The product was obtained as white solid (0.60 mmol scale, 176 
mg, 82%). 1H-NMR (500 MHz) CDCl3: δ = 8.30 – 8.23 (m, ArH, 
2H), 7.77 – 7.71 (m, ArH, 2H), 7.55 – 7.51 (m, ArH, 1H), 7.49 – 
7.45 (m, ArH, 3H), 7.45 – 7.41 (m, ArH, 3H), 7.29 (d, 3JHH = 8.0 
Hz, ArH, 1H), 6.94 (d, 3JHH = 8.0 Hz, ArH, 1H), 4.96 (d, 2JHH = 10.5 
Hz, COCH2, 1H), 4.03 (d, 2JHH = 10.5 Hz, COCH2, 1H). 13C-NMR 
(126 MHz) CDCl3: δ = 170.3 (C=O), 168.3 (C=N), 146.7 (ArC), 
146.0 (ArC), 142.7 (ArC), 138.4 (ArC), 131.4 (ArC), 130.8 (ArC), 
130.4 (ArC), 130.3 (ArC), 129.4 (ArC x 2), 128.5 (ArC x 2), 128.4 
(ArC x 2), 125.4 (ArC), 125.0 (ArC),  124.5 (ArC x 2), 57.4 
(COCH2). HRMS-ESI (m/z) calculated for C21H15N3O3 [+H] +: 
358.1186, found: 358.1187. LCMS purity (UV) = 95%, tR 18.35 
min. 
1-(4-Nitrophenyl)-3-benzyl-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3e) 
The product was obtained as white solid (0.40 mmol scale, 140 
mg, 78%). 1H-NMR (500 MHz) CDCl3: δ = 8.27 – 8.21 (m, ArH, 
2H), 7.67 (d, 3JHH = 7.5 Hz, ArH, 2H), 7.52 – 7.48 (m, 1H), 7.47 – 
7.43 (m, ArH, 2H), 7.41 – 7.37 (m, ArH,  5H), 7.36 – 7.30 (m, ArH, 
3H), 7.25 – 7.21 (m, ArH, 2H), 6.90 (d, 3JHH = 8.0 Hz, ArH, 1H), 
4.01 (dd, J = 7.5, 6.0 Hz, COCHCH2, 1H), 3.68 (dd, 2,3JHH = 14.0, 6.0 
Hz, COCHCH2, 1H), 3.62 (dd, 2,3JHH  = 14.0, 7.5 Hz, COCHCH2, 1H). 
13C-NMR (126 MHz) CDCl3: δ = 168.8 (C=O), 168.5 (C=N), 147.1 
(ArC), 145.9 (ArC), 142.1 (ArC), 138.9 (ArC), 138.4 (ArC), 131.5 
(ArC), 130.8 (ArC), 130.5 (ArC), 130.3 (ArC), 130.0 (ArC x 2), 
129.5 (ArC x 2), 128.6 (ArC x 2), 128.5 (ArC x 2),  128.3 (ArC x 
2),  126.3 (ArC), 125.3 (ArC), 125.1 (ArC), 124.5 (ArC x 2), 65.6 
(COCHCH2), 37.9 (COCHCH2). HRMS-ESI (m/z) calculated for 
C28H21N3O3 [+H] +: 448.1656, found: 448.1669. LCMS purity (UV) 
=  99 %, tR 20.81 min. 
7-Chloro-1-(4-nitrophenyl)-3-benzyl-5-phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one (3f) 
The product was obtained as white solid (0.15 mmol scale, 54 
mg, 75%). 1H-NMR (500 MHz) CDCl3: δ = 8.26 (d, 3JHH  = 8.5 Hz, 
ArH, 2H), 7.66 (d, 3JHH  = 7.5 Hz, ArH, 2H), 7.57 – 7.50 (m, ArH, 
1H), 7.51 – 7.44 (m, ArH, 2H), 7.42 – 7.36 (m, ArH, 3H), 7.34 – 
7.30 (m, ArH, 2H), 7.26 (s, ArH, 3H), 7.17 (d, J = 8.7 Hz, ArH, 1H), 
6.85 (d, 3JHH = 8.5 Hz, ArH, 1H), 3.99 (dd, J = 7.5, 6.0 Hz, 
COCHCH2, 1H), 3.70 – 3.57 (m, COCHCH2, 2H). 13C-NMR (126 
MHz) CDCl3: δ = 168.4, (C=O), 167.2 (C=N), 146.6 (ArC), 146.1 
(ArC), 140.6 (ArC), 138.6 (ArC), 137.7 (ArC), 131.7 (ArC), 131.1 
(ArC), 129.9 (ArC x 2),  129.8 (ArC), 129.5 (ArC x 2), 128.7 (ArC 
x 2), 128.6 (ArC x 2), 128.3 (ArC x 2), 126.5 (ArC), 126.4 (ArC), 
126.2 (ArC), 124.6 (ArC x 2), 119.3 (ArC) 65.8 (COCHCH2), 37.9 
(COCHCH2). HRMS-ESI (m/z) calculated for C28H20ClN3O3 [+H] +: 
482.1266, found: 482.1286. LCMS purity (UV) =  95%, tR  19.71 
min. 
1-(4-Nitrophenyl)-3-benzyl-5-(pyridine-2-yl)-1,3-dihydro-
2H-1,4-benzodiazepin-2-one (3g) 
The product was obtained as white solid (0.11 mmol scale, 38 
mg, 77%). 1H-NMR (500 MHz) CDCl3: δ = 8.67 – 8.62 (m, ArH, 
1H), 8.15 (d, 3JHH  = 8.0 Hz, ArH, 2H), 8.18 – 8.12 (m, ArH, 1H), 
7.88 – 7.81 (m, ArH, 1H), 7.44 – 7.42 (m, ArH, 2H), 7.42 – 7.37 
(m, ArH, 4H), 7.35 – 7.26 (m, ArH, 3H), 7.25 – 7.21 (m, ArH, 2H), 
6.89 (d, 3JHH  = 8.0 Hz, ArH, 1H), 4.10 (dd, 3JHH  = 8.0, 6.0 Hz, 
COCHCH2, 1H), 3.70 (dd, 2,3JHH  = 14.0, 7.0 Hz, COCHCH2, 1H), 
3.62 (dd, 2,3JHH  = 14.0, 7.5 Hz, COCHCH2, 1H). 13C-NMR (126 
MHz) CDCl3: δ = 168.6  (C=O), 167.6  (C=N), 155.9  (ArC), 148.7 
(ArC), 147.1  (ArC), 145.9  (ArC), 141.9 (ArC), 138.9 (ArC), 136.8 
(ArC), 131.4 (ArC), 130.8  (ArC), 129.9 (ArC x 2), 128.8 (ArC x 2), 
128.3 (ArC x 2), 126.3 (ArC), 125.2 (ArC), 125.1 (ArC), 124.8 
(ArC x 2), 124.4 (ArC x 2), 123.8 (ArC), 65.8  (COCHCH2), 37.8 
(COCHCH2). HRMS-ESI (m/z) calculated for C27H20N4O3 [+H] +: 
449.1608, found: 449.1617. LCMS purity (UV) =  99 %, tR 20.81 
min. 
1-(4-Nitrophenyl)-3-benzyl-5-(2’-fluorobiphenyl-2-yl)-1,3-
dihydro-2H-1,4-benzodiazepin-2-one (3h) 
The product was obtained as white solid (0.03 mmol scale, 11 
mg, 70%). 1H-NMR (500 MHz) CDCl3: δ = 8.14 (d, 3JHH = 8.5 Hz, 
ArH, 2H), 7.57 – 7.52 (m, ArH, 1H), 7.51 – 7.45 (m, ArH, 1H), 
7.42 (d, 3JHH = 7.5 Hz, ArH, 1H), 7.38 (d, 3JHH = 7.5 Hz, ArH, 1H), 
7.32 – 7.27 (m, ArH, 7H), 7.26 – 7.19 (m, ArH, 2H), 7.15 – 7.09 
(m, ArH, 1H), 7.06 (d, 3JHH = 7.5 Hz, ArH, 1H), 7.00 – 6.93 (m, 
ArH, 3H), 6.65 (d, 3JHH = 8.5 Hz, ArH, 1H), 3.80 (dd, 3JHH = 8.0, 5.5 
Hz, COCHCH2, 1H), 3.69 (d, 3JHH = 8.0 Hz, COCHCH2, 1H), 3.66 (d, 
3JHH = 8.0 Hz, COCHCH2, 1H). 13C-NMR (126 MHz) CDCl3: δ = 
169.5 (C=O), 167.9 (C=N), 159.2 (d, 1JFC = 247.5 Hz, ArC) 147.1 
(ArC), 145.7 (ArC), 141.5 (ArC), 138.8 (ArC), 138.7 (ArC), 135.7 
(ArC), 132.0 (d, 3JFC = 3.5 Hz, ArC), 131.6 (ArC), 131.4 (ArC), 
130.8 (ArC), 130.3 (ArC), 129.9 (ArC x 2), 129.8 (ArC), 129.5 
(ArC), 129.2 (ArC), 128.9 (d, 3JFC = 8.0 Hz, ArC), 128.5 (ArC x 2), 
128.3 (ArC x 2),  128.1 (ArC),  126.3 (ArC), 125.2 (ArC), 124.8 
(ArC), 124.5 (d, 4JFC = 3.5 Hz, ArC), 124.2 (ArC x 2), 115.4 5 (d, 
2JFC = 22.0 Hz, ArC) 66.0 (COCHCH2), 37.8 (COCHCH2). HRMS-ESI 
(m/z) calculated for C34H24N3O3 [+H] +: 542.1874, found: 
542.1881. LCMS purity (UV) =  93%, tR 23.27 min. 
1-(2,4,6-Trimethylphenyl)-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3i) 
The reaction was run for 8 hours. The product was obtained as 
white solid (1.00 mmol scale, 181 mg, 51%).  1H NMR (500 MHz, 
DMSO-d6) δ 7.60 – 7.57 (m, ArH, 2H), 7.54 – 7.46 (m, ArH, 4H), 
7.32 (d, 3JHH = 8.0 Hz, ArH, 1H), 7.27 – 7.23 (m, ArH, 1H), 7.10 – 
7.07 (m, ArH, 1H), 6.88 (s, ArH, 1H), 6.78 (d, 3JHH  = 8.0, 1.1 Hz, 
ArH, 1H), 4.70 (d, 2JHH  = 10.0 Hz, COCH2,1H), 4.04 (d, 2JHH  = 10.0 
Hz, COCH2, 1H), 2.26 (s, CH3, 3H), 2.24 (s, CH3, 3H), 1.61 (s, CH3, 
3H). 13C-NMR (126 MHz) DMSO-d6: δ = 170.3 (C=O), 167.5 
(C=N), 142.2 (ArC), 138.9 (ArC), 137.9 (ArC), 137.0 (ArC), 136.2 
(ArC), 134.7 (ArC), 132.3 (ArC), 130.9 (ArC), 130.0 (ArC x 2), 
129.6 (ArC x 2), 129.5 (ArC), 128.9 (ArC x 2),  128.7 (ArC), 124.4 
(ArC), 122.1 (ArC), 57.3 (COCH2), 21.0 (CH3), 18.5(CH3), 17.5 
(CH3). HRMS-ESI (m/z) calculated for C24H22N2O [+H] +: 
355.1805, found: 355.1804. LCMS purity (UV) = 97%, tR 21.13 
min. 
1-(2-Bromophenyl)-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3j) 
The reaction was run for 8 hours. The product was obtained as 
white solid (1.00 mmol scale, 31 mg, 8%). 1H NMR (500 MHz, 
DMSO-d6) δ 7.84 (d, 3JHH = 8.0 Hz, ArH, 1H), 7.70 (d, 3JHH = 8.0 Hz, 
ArH, 1H), 7.66 – 7.59 (m, ArH, 4H), 7.52 – 7.46 (m, ArH, 3H), 
7.41 – 7.37 (m, ArH, 1H), 7.32 (dd, J = 7.8, 1.7 Hz, ArH, 1H), 7.27 
(d, 3JHH = 7.0 Hz, ArH, 1H), 6.92 – 6.83 (m, ArH, 1H), 4.69 (d, 2JHH 
= 10.5 Hz, COCH2, 1H), 4.01 (d, 2JHH = 10.5 Hz, COCH2, 1H). 13C-
NMR (126 MHz) CDCl3: δ = 170.7 (C=O), 168.9 (C=N), 142.0 
(ArC), 138.9 (ArC), 138.6 (ArC), 134.3 (ArC), 133.7 (ArC), 132.0 
(ArC), 131.0 (ArC), 130.9 (ArC), 130.8 (ArC), 129.9 (ArC x 2), 
129.8 (ArC), 129.1 (ArC), 128.8 (ArC x 2), 124.7 (ArC), 123.0 
(ArC), 121.5 (ArC), 57.0 (COCH2). HRMS-ESI (m/z) calculated for 
C21H15BrN2O [+H] +: 391.0441, found: 391.0457. LCMS purity 
(UV) = 93%, tR 15.23 min. 
1-(3’-Trifluoromethylphenyl)-5-phenyl-1,3-dihydro-2H-1,4-
benzodiazepin-2-one (3k) 
The reaction was run for 8 hours. The product was obtained as 
white solid (0.50 mmol scale, 80 mg, 42%). 1H-NMR (500 MHz) 
CDCl3: δ = 7.72 (d, 3JHH = 7.5 Hz, ArH, 2H), 7.60 – 7.55 (m, ArH, 
2H), 7.53 (d, 3JHH = 8.5 Hz, ArH, 2H), 7.49 – 7.45 (m, ArH, 2H), 
7.44 – 7.38 (m, ArH, 3H), 7.25 – 7.20 (m, ArH, 1H), 6.92 (d, 3JHH = 
8.5 Hz, ArH, 1H), 4.95 (d, 2JHH = 10.5 Hz, 1H), 4.02 (d, 2JHH = 10.5 
Hz, 1H). 13C-NMR (126 MHz) CDCl3: δ = 170.3 (C=O), 168.3 
(C=N), 143.1 (ArC), 141.3 (ArC), 138.6 (ArC), 132.0(q, 2JFC = 29.9 
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Hz, ArC),131.9 (ArC), 131.6 (ArC), 131.4 (ArC), 130.7 (ArC), 
130.4 (ArC), 129.8 (ArC x 2), 129.5 (ArC), 128.5 (ArC x 2), 125.2 
(q, 3JFC = 3.5 Hz, ArC), 124.8(ArC), 124.8(ArC), 123.5 (q, 1JFC = 
273.0 Hz, ArC), 124.2 (q, 3JFC = 3.5 Hz, ArC), 57.3 (COCH2). 
HRMS-ESI (m/z) calculated for C22H15F3N2O [+H] +: 381.1209, 
found: 381.1208. LCMS purity (UV) = 96%, tR 21.35 min. 
1-Phenyl-5-phenyl-1,3-dihydro-2H-1,4-benzodiazepin-2-
one (3l) 
The reaction was run for 8 hours. The product was obtained as 
white solid (0.50 mmol scale, 14 mg, 9%). 1H-NMR (500 MHz) 
CDCl3: δ = 7.72 (d, 3JHH = 7.5 Hz, ArH, 2H), 7.54 – 7.49 (m, ArH, 
1H), 7.47 (d, 3JHH = 7.5 Hz, ArH, 2H), 7.43 – 7.38 (m, ArH, 2H), 
7.37 – 7.30 (m, ArH, 2H), 7.24 – 7.21 (m, ArH, 3H), 7.20 – 7.16 
(m, ArH, 1H), 6.97 (d, 3JHH = 8.5 Hz, ArH, 1H), 4.96 (d, 2JHH = 10.5 
Hz, ArH, COCH2, 1H), 4.01 (d, 2JHH = 10.5 Hz, COCH2, 1H). 13C-
NMR (126 MHz) CDCl3: δ = 170.7 (C=O), 168.3 (C=N), 146.5 
(ArC), 143.3 (ArC), 140.7 (ArC), 138.6 (ArC), 131.3 (ArC), 130.7 
(ArC), 130.3 (ArC), 129.6 (ArC x 2), 129.3 (ArC x 2), 128.4 (ArC x 
2), 128.3 (ArC x 2), 127.5 (ArC), 124.7 (ArC),  124.2 (ArC), 57.2 
(COCH2). HRMS-ESI (m/z) calculated for C21H16N2O [+H] +: 
313.1335, found: 313.1338. LCMS purity (UV) = 90%, tR 16.10 
min. 
1-(4-Nitrophenyl)-3-(4-nitrophenyl)-5-phenyl-1,3-dihydro-
2H-1,4-benzodiazepin-2-one (7) 
The product was obtained as white solid (0.60 mmol scale, 2 eq. 
of diaryliodonium triflate, 146 mg, 51%). 1H-NMR (500 MHz) 
CDCl3: δ = 8.34 – 8.22 (m, ArH, 4H), 7.85 – 7.79 (m, ArH, 2H), 
7.77 – 7.71 (m, ArH, 2H), 7.74 – 7.57 (m, ArH, 3H), 7.59 – 7.50 
(m, ArH, 3H), 7.41 – 7.32 (m, ArH, 2H), 7.07 – 7.02 (m, ArH, 1H). 
13C-NMR (126 MHz) CDCl3: δ = 166.0 (C=O), 158.3 (C=N), 149.1 
(ArC), 146.7 (ArC), 145.6 (ArC), 144.1 (ArC), 143.3 (ArC), 135.0 
(ArC), 132.6 (ArC), 131.5 (ArC), 129.9 (ArC), 129.6 (ArC), 129.5 
(ArC x 2), 128.9 (ArC x 2), 126.8 (ArC x 2), 126.3 (ArC), 125.4 
(ArC) 124.5 (ArC x 2), 124.3 (ArC x 2), 121.3 (ArC x 2). HRMS-
ESI (m/z) calculated for C26H17N5O5 [+H] +: 480.1230 found: 
480.1245. LCMS purity (UV) = 95%, tR 18.35 min. 
1,1’-Oxybis(4-nitrobenzene) (10) 
To a solution of (4-nitrophenyl)phenyliodonium triflate (30 mg, 
0.06 mmol) in DCE (1 mL) was added sodium hydroxide (aq., 1 
mL) and stirred for 20 min. at room temperature. Upon 
completion, the reaction was diluted with dichloromethane (5 
mL x 3) and the layers were separated. Combined organic layers 
were dried (MgSO4) and concentrated under reduced pressure 
to afford the product as a white powder (7 mg, 43%). 1H-NMR 
(500 MHz) CDCl3: δ = 8.33 – 8.27 (m, ArH, 4H), 7.19 – 7.14 (m, 
ArH, 4H).13C-NMR (126 MHz) CDCl3: δ = 160.6 (ArC x 2), 144.2 
(ArC x 2), 126.2 (ArC x 4), 119.3 (ArC x 4). HRMS-ESI (m/z) 
calculated for C12H8N2O5 [+H] +: 261.0511, found: 261.0513.  
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